XENE XENON PHARMACEUTICALS INC Management Changes 8-K Filing 2025 - Management Change Christopher Von Seggern has left his position as Chief Commercial Officer of Xenon Pharmaceuticals, receiving severance and entering a consulting agreement until May 2025.Get access to all SEC 8-K filings of the XENON PHARMACEUTICALS INC